Effects of HMG-CoA Reductase Inhibitors on Cardiovascular Events and Renal Function in Patients with Chronic Kidney Disease
碩士 === 高雄醫學大學 === 臨床藥學研究所 === 101 === Background: In Taiwan, the prevalence of chronic kidney disease (CKD) among adult is 12%. CKD is one of the risk factors of cardiovascular disease (CVD). HMG-CoA reductase inhibitors (statin) is the first-line agent for treatment of hypercholesterolemia. There a...
Main Authors: | Chieh-Ying Chen, 陳潔瑩 |
---|---|
Other Authors: | Shang-Jyh Hwang |
Format: | Others |
Language: | zh-TW |
Published: |
2012
|
Online Access: | http://ndltd.ncl.edu.tw/handle/29967318275485345655 |
Similar Items
-
The role of HMG-CoA reductase inhibitors in cardiovascular risk reduction
by: McIntyre, Christine
Published: (2004) -
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
by: Suetonia C. Palmer, et al. -
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
by: Suetonia C. Palmer, et al. -
Pleiotropic effects of the HMG-CoA reductase inhibitors
by: Mihos CG, et al.
Published: (2011-04-01) -
The discovery and development of HMG-CoA reductase inhibitors.
by: A Endo
Published: (1992-11-01)